Exploring height outcomes with adjuvant aromatase inhibition in growth hormone–deficient male survivors of childhood cancer

Abstract

AbstractBackgroundAromatase inhibitors (AI) may improve height in short stature conditions; however, the effect in childhood cancer survivors (CCS) is unknown. We assessed final adult height (FAH) in CCS treated with AI and GH compared with those treated with GH alone.MethodsRetrospective cohort study of GH‐deficient male CCS treated between 2007 and 2023. FAH was noted as the height at the fusion of growth plates or 18 years of age. Multivariable linear regression was used to examine treatment association with FAH, adjusting for other risk factors.ResultsNinety‐two patients were included; 70 were treated with GH and 22 with combination AI/GH. The mean age at GH initiation did not differ between groups. The mean age at AI initiation was 13.7 ± 1.9 years. A greater proportion of patients in the AI/GH group were treated with stem cell transplantation, abdominal radiation, total body irradiation, and cis‐retinoic acid (p < .01). Multivariable linear regression demonstrated no significant treatment association with FAH Z‐score (β = 0.04, 95% CI: −0.9 to 0.9). History of spinal radiation (β = −0.93, 95% CI: −1.7 to −0.2), lower starting height Z‐score (β = −0.8, 95% CI: −1.2 to −0.4), and greater difference between bone age and chronological age (β = −0.3, 95% CI: −0.5 to −0.07) were associated with lower FAH Z‐score.ConclusionsAdjuvant AI was not associated with increased FAH in male CCS compared with GH monotherapy. Future work is needed to determine the optimal adjunctive treatment to maximize FAH for this population.